Trial Profile
A Phase 1, Open-Label, Parallel Group Study to Determine the Pharmacokinetics, Safety and Tolerability of Rucaparib in Patients With an Advanced Solid Tumor and Either Moderate Hepatic Impairment or Normal Hepatic Function
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Sep 2023
Price :
$35
*
At a glance
- Drugs Rucaparib (Primary)
- Indications Colon cancer; Liver cancer; Neuroendocrine tumours; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Clovis Oncology [CEASED]; zr pharma
- 19 May 2021 Status changed from active, no longer recruiting to completed.
- 09 Feb 2021 Planned End Date changed from 30 Dec 2020 to 30 Mar 2021.
- 29 Jul 2020 Planned End Date changed from 30 Jun 2020 to 30 Dec 2020.